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Introduction: Islet transplantation is one of the most promising therapeutic approaches for patients with
severe type 1 diabetes mellitus (T1DM). Transplantation of engineered islet cell sheets holds great po-
tential for treating T1DM as it enables the creation of stable neo-islet tissues. However, a large mass of
islet cell sheets is required for the subcutaneous transplantation to reverse hyperglycemia in diabetic
mice. Here, we investigated whether the liver surface could serve as an alternative site for islet cell sheet
transplantation.
Methods: Dispersed rat islet cells (0.8  106 cells) were cultured on laminin-332-coated thermores-
ponsive culture dishes. After 2 days of cultivation, we harvested the islet cell sheets by lowering the
culture temperature using a support membrane with a gelatin gel. We transplanted two recovered islet
cell sheets into the subcutaneous space or onto the liver surface of severe combined immunodeﬁciency
(SCID) mice with streptozocin-induced diabetes.
Results: In the liver surface group, the non-fasting blood glucose level decreased rapidly within several
days after transplantation. In marked contrast, the hyperglycemia state was maintained in the subcu-
taneous space transplantation group. The levels of rat C-peptide and insulin in the liver surface group
were signiﬁcantly higher than those in the subcutaneous space group. An immunohistological analysis
conﬁrmed that most of the islet cells engrafted on the liver surface were insulin-positive. The CD31-
positive endothelial cells formed vascular networks within the neo-islets and in the surrounding tis-
sues. In contrast, viable islet cells were not found in the subcutaneous space group.
Conclusions: Compared with the subcutaneous space, a relatively small mass of islet cell sheets was
enough to achieve normoglycemia in diabetic mice when the liver surface was selected as the trans-
plantation site. Our results demonstrate that the optimization of the transplantation site for islet cell
sheets leads to signiﬁcant improvements in the therapeutic efﬁciency for T1DM.
© 2018, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Type 1 diabetes mellitus (T1DM) is an autoimmune disease with
progressive destruction of insulin-producing pancreatic b-cells.
Individuals with T1DM need lifelong administrations of exogenous
insulin through multiple daily subcutaneous injections. In some
individuals with severe T1DM, it is very difﬁcult to achieve better
glycemic control by insulin administrations, and such individuals
thus experience repeated hypoglycemic episodes and occasionally
develop fatal hypoglycemia. Islet transplantation has high potential
for the treatment of patients with severe T1DM as an alternative
therapy to insulin replacement or whole pancreas transplantation.sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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dependence in all seven patients with T1DMusing a glucocorticoid-
free immunosuppressive regimen after the infusion of islets into the
portal vein of the patients [1]. This approach, the so-called
Edmonton protocol, attracted worldwide attention as a therapeu-
tic breakthrough in islet transplantation. Since then, much progress
in the islet manufacturing processes and immunosuppression reg-
imens has been made, resulting in signiﬁcant improvements in
the rates of 5-year insulin independence from only approx. 10% [2]
to >50% [3].
In clinical studies, the intrahepatic transplantation of islets
through the portal vein is the most prevalent method, with mini-
mal invasiveness. Physiologically, endogenous insulin secreted
from the pancreas ﬂows primarily into the liver through the portal
vein and is consumed there, and then acts on muscle and adipose
tissues. The non-physiological insulin distribution by subcutaneous
injections therefore causes inadequate glycemic control in T1DM
patients [4]. In contrast, for insulin secreted from the transplanted
intrahepatic islets, it is possible to reproduce the physiological in-
sulin action [5,6].
The liver as a transplantation site enables an efﬁcient supply of
oxygen and nutrition from the hepatic sinusoids to the trans-
planted islets. However, there is a critical weakness in the intra-
hepatic islet transplantation; in a study of this technique, approx.
60% of the transplanted islets were lost in the very early stage of the
post-transplantation period [7]. Instant blood-mediated inﬂam-
matory reaction (IBMIR) is a nonspeciﬁc immune reaction triggered
by the activation of coagulation factors and the complement system
through a direct exposure of the graft cells to blood [8,9], which
causes the loss of the transplanted islets. Islets isolated from mul-
tiple donors were therefore required to achieve normoglycemia in
the majority of clinical islet-transplantation trials [3], and this has
hampered the standardization and wide adaptation of the current
islet transplantation therapies for T1DM.
Our research group has developed cell sheet technology for
regenerative therapy and tissue engineering. We prepared contig-
uous monolayer cell sheets using temperature-responsive cell
culture dishes in a noninvasive manner [10], which could be
directly transplanted to host tissues (e.g., liver, heart, subcutaneous
space, cornea, esophagus, and periodontal ligaments) without
necessitating adhesive agents [11,12]. In fact, cell sheet technology
has been applied in several clinical trials including those for
regeneration therapies of myocardial tissue, cornea, esophageal
mucosa, lung, and periodontal ligament [13e18].
We reported a new proof-of-concept therapeutic approach to
create functional neo-islet tissues in the subcutaneous space of
diabetic mice by transplanting islet cell sheets [19,20]. This
approach has several advantages for islet transplantation in terms
of the potentially lesser IBMIR, high accessibility to the grafts, and
less-invasive transplantation procedure. However, there is a critical
problem regarding islet cell sheet transplantation in the subcu-
taneous space; a large mass of islet cells (total 1.1  107 cells per
mouse) was required to achieve euglycemia in streptozocin (STZ)-
induced diabetic model mice. The inadequate vascularization and
the poor supply of blood ﬂow in the subcutaneous space [21] may
not be suitable for islet cell sheet transplantation, because the ox-
ygen supply limitation causes a restriction of islet cell survival and
function [22e24]. The nonphysiological action of insulin secreted
from the subcutaneous space was also considered to be
problematic.
In the present study, we investigated whether there is an
alternative, more favorable place for islet cell sheet transplantation.
We selected the liver surface as a new transplantation site, where
the transplanted cell sheets could be indirectly but effectively
exposed to the blood supply. We performed the transplantation ofislet cell sheets onto the liver surface of diabetic mice and
compared the transplantation efﬁciency and therapeutic values
between the liver surface group and subcutaneous space group.
2. Materials and methods
2.1. Animals
All animal experiments were performed with the approval of
the Institutional Animal Care and Use Committee of Tokyo
Women's Medical University. Male Lewis rats, 8e12 weeks of age
(LEW/CrlCrlj, Charles River, Yokohama, Japan) were used as donors
for islet cell sheet transplantation. Male severe combined immu-
nodeﬁcient (SCID) mice, 7e10 weeks of age (C.B-17/lcr-scid/scidJcl,
CLEA Japan, Tokyo) were used as recipients. Diabetes was induced
in the SCID mice by a single intraperitoneal injection of strepto-
zocin (220 mg/kg body weight). Non-fasting blood glucose levels
weremeasured in blood samples collected from the tail vein of each
mousewith the use of a handheld blood glucosemeter (Glutest Neo
Super; Sanwa Chemistry Laboratory, Nagoya, Japan). SCID mice
with hyperglycemia greater than a non-fasting blood glucose level
of 350 mg/dL were used for the transplantation of islet cell sheets.
All animals were kept under a controlled environment (22e24 C,
55 ± 10% humidity, and a 12-h light/dark cycle).
2.2. Islet isolation and preparation of single islet cells
We isolated pancreas islets from Lewis rats by collagenase
digestion as described [20,24] with slight modiﬁcations. Each
pancreas tissue was swollen by an injection of 2 mg/mL collagenase
type V (SigmaeAldrich, St. Louis, MO) in Hanks' balanced salt so-
lution (SigmaeAldrich) through the common bile duct. The har-
vested pancreas was further digested at 37 C for 12 min.
Subsequently, islets were puriﬁed by discontinuous gradient
centrifugation using 1.119, 1.100, and 1.077 g/mL Histopaque (Sig-
maeAldrich) and then cultured overnight in the cell culture me-
dium, RPMI 1640 medium (Thermo Fisher Scientiﬁc, Waltham, MA)
supplemented with 10% fetal bovine serum (FBS; Japan Bio Serum,
Hiroshima, Japan), 5.5 mmol/L glucose (Thermo Fisher Scientiﬁc),
10 mmol/L HEPES (Thermo Fisher Scientiﬁc), 1 mmol/L sodium
pyruvate (Thermo Fisher Scientiﬁc), 0.1 mmol/L nonessential amino
acids (Thermo Fisher Scientiﬁc), 2 mmol/L GlutaMAX-I (Thermo
Fisher Scientiﬁc), 100 IU/mL penicillin, and 100 mg/mL streptomycin
(SigmaeAldrich) at 37 C in 5% CO2. Islets were treated with 0.125%
trypsineEDTA solution (Thermo Fisher Scientiﬁc) to obtain single
cell suspensions. The viability of dispersed islet cells was assessed
by a trypan blue dye exclusion test. The dispersed islet cells with a
viability exceeding 90% were used for preparing islet cell sheets.
2.3. Fabrication of islet cell sheets
Single islet cells were cultured on temperature-responsive cul-
ture dishes (TRDs) to obtain monolayer cell sheets as described
[19,20]. The 24-well cell culture plates were covalently grafted with
a triple amount of the temperature-responsive polymer [poly(N-
isopropylacrylamide)] compared to that of commercially available
dishes (UpCell; CellSeed, Tokyo) and were subsequently coated
with human laminin-332 (0.2 mg/cm2; ReproCELL, Yokohama,
Japan) at 37 C for 2 h to promote the attachment of islet cells [25].
Subsequently, a 10 mm 10mm cloning cylinder (MerckMillipore,
Billerica, MA) was placed in each well. The islet cells were seeded at
0.8  106 cells, which correspond to the number of cells composing
~850 IEQ (islet equivalents) [26], per well into the cloning cylinders
placed on the laminin-332 coated TRDs. Islet cells were cultured to
conﬂuence for 2 days in the cell culture medium.
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To transfer islet cell sheets onto the liver surface and the sub-
cutaneous space in mice, we recovered islet cell sheets from TRDs
using an in situ gelation method as described [27] with slight
modiﬁcations. Gelatin powder (RM-100; Jellice, Miyagi, Japan) was
dissolved in Hanks' balanced salt solution (SigmaeAldrich) at a
concentration of 16% (w/v) at 37 C for 60 min. The gelatin solution
was kept at 37 C in a water bath until its use in experiments. The
cloning cylinder and the culture mediumwere removed from TRDs
at 2 days after the inoculation of the islet cells. The gelatin solution
was poured onto each culture dish. Thereafter, a supporting
membrane (Cell Shifter; CellSeed) was placed onto the gelatin so-
lution, and the culture plate was incubated at 20 C for 60 min to
promote the gelation of the gelatin solution. The membrane with
the gelatin gel attached to an islet cell sheet was slowly removed
from TRDs for transplantation (Fig. 1).
2.5. Transplantation of islet cell sheets
Under anesthesia using isoﬂurane, two sheets of the islet cells
(total 1.6 106 cells)were transplanted onto the liver surface (n¼ 7)
or into the subcutaneous space (n¼ 7) of STZ-induced diabetic SCID
mice. In the liver surface transplantation, we gently scratched a 10-
mm2 area on the surface of the left lateral lobe of the recipient liver
with a cotton swab to remove the liver capsule before transplantingFig. 1. Schematic of the recovery and transplantation of rat islet cell sheets from a temper
seeded into a cloning cylinder placed on a laminin-332 coated TRD and cultured for 2 days
transplanted onto the liver surface or the subcutaneous spaces of STZ-induced diabetic SCIthe islet cell sheets. After hemostasis was achieved by applying
pressure with cotton swabs, an islet cell sheet with the support
membrane and the gelatin gel was transplanted onto the scratched
liver surface. Subsequently, the support membrane was removed
slowly from the gelatin gel. The gelatin gel was liqueﬁed by the body
temperature ofmouse shortly after transplantation. After the gelatin
gel melted, these steps were repeated once for the subsequent
transplantation of another islet sheet. Lastly, two islet cell sheets on
the left lateral lobe of the liver were covered by the median lobe of
the liver. It is notable that the experimental results for the cell sheet
transplantation onto the scratched liver surface were more repro-
ducible compared with those onto the intact liver surface.
In the subcutaneous space transplantation, an L-shaped incision
was made on the left side of the abdomen of the recipient mouse,
and a subcutaneous space was created by exfoliating the layers of
skin. An islet cell sheet with the support membrane and the gelatin
gel was transplanted on the superﬁcial fascial layer in the subcu-
taneous space. The support membrane was then removed from the
gelatin gel. Another islet cell sheet was transplanted on the top of
the transplanted islet cell sheet in the same way (Fig. 1).
2.6. Measurement of serum insulin and C-peptide
Mouse blood samples were obtained at days 0, 14, and 28. The
levels of serum insulin, rat-speciﬁc C-peptide, and mouse-speciﬁc
C-peptide were measured using the Rat Insulin ELISA kitature-responsive dish (TRD) using a gelatin/membrane. Dispersed rat islet cells were
at 37 C. The islet cell sheets were recovered from TRDs using gelatin/membranes and
D mice.
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codi), and theMouse C-peptide ELISA kit (Mercodi) according to the
manufacturer's instruction, respectively. The Rat Insulin Elisa kit
shows cross-reactivity with mouse insulin.
2.7. Intraperitoneal glucose tolerance tests
To evaluate the functionality of the transplanted islet cell sheets,
we conducted the intraperitoneal glucose tolerance test on day 28.
After 6 h of fasting, mice were inoculated with a glucose solution
(0.22 mg/g body weight) intraperitoneally. Blood samples were
collected at 0, 15, 30, 60, 90 and 120 min after the glucose
administration.
2.8. Histochemical analysis
Tissue samples from dissectedmice at day 28were ﬁxedwith 4%
paraformaldehyde solution (Wako, Osaka, Japan) overnight and
embedded in parafﬁn, and we used a microtome to prepare 5-mm-
thick sections for hematoxylineeosin (H&E) staining and an
immunohistochemical analysis. For the immunohistochemical
analysis, the sections were incubated with 10% goat serum for
30 min and then incubated with guinea pig polyclonal anti-insulin
antibody, mouse monoclonal anti-glucagon antibody, rabbit poly-
clonal anti-CD31 antibody, or rabbit monoclonal anti-Ki67 antibody
(all from Abcam, Cambridge, MA) overnight. The bound antibodies
were detected by Alexa Fluor 488-conjugated anti-guinea pig IgG,
Alexa Fluor 594-conjugated anti-mouse IgG, or Alexa Fluor 594-
conjugated anti-rabbit IgG (Thermo Fisher Scientiﬁc) as second-
ary antibodies. The stained sections were mounted using ProLong
gold antifade reagent with DAPI (Thermo Fisher Scientiﬁc). The
Ki67-labeling index of the b cells in the neo-islet tissues was
determined by calculating the ratio of Ki67-positive nuclei to
insulinþ-b cells in randomly selected ﬁelds of liver sections from 5
individual mice (n ¼ 5).
2.9. Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) method
Five-mm parafﬁn sections were double-stained by the TUNEL
method for apoptotic nuclei and by immunohistochemistry of in-
sulin for b cells. Apoptotic nuclei were detected using ApopTag Red
In Situ Apoptosis Detection Kit (Merck Millipore) according to the
manufacturer's instructions. Subsequently, immunohistochemistry
for insulin was performed using guinea pig polyclonal anti-insulin
antibody (Abcam).
2.10. Statistical analysis
All data are presented as the mean ± standard error of the mean
(SEM). Statistical analyses were performed using IBM SPSS Statis-
tics 18 software (IBM Japan, Tokyo). For comparisons between two
groups, Student's t-test or theManneWhitney U-test was used. The
statistical signiﬁcance of differences among three or more groups
was determined by an analysis of variance (ANOVA) followed by
Tukey's honestly signiﬁcant difference (HSD) or Games Howell
post-hoc test. The statistical signiﬁcance of differences is indicated
by asterisks (*p < 0.05).
3. Results
3.1. Transplantation efﬁcacy of islet cell sheets onto the liver surface
We harvested the rat islet cell sheets from the TRDs by using the
support membrane with the gelatin gel (Fig. 1). For the comparisonof the transplantation efﬁciencies of the islet cell sheets for the liver
surface and the subcutaneous space groups, the same amount of
islet cells (two cell sheets with a total of 1.6  106 cells) were
transplanted. Cell sheets were transplanted onto the surface of the
capsule-removed liver surface or into the subcutaneous space of
diabetic SCID mice. The level of nonfasting blood glucose in the
liver surface group (n ¼ 7) achieved normoglycemia within a few
days after transplantation, and it was maintained at least for 28
days (Fig. 2A). In marked contrast, the state of hyperglycemia was
maintained in the subcutaneous space group. The blood glucose
level remained at >300 mg/dL in the subcutaneous group (n ¼ 7),
although this value was slightly and temporary decreased at 2e7
days after transplantation in comparison with that in the non-
transplanted control group.
The body weight of the mice gradually increased in the liver
surface group, indicating that good glycemic control was achieved
(Fig. 2B). By contrast, restoration of the body weight was prevented
in both the nontransplanted group and the subcutaneous space
group.
3.2. Insulin and c-peptide secretory capabilities of transplanted islet
cell sheets
The serum insulin concentration was extremely low (approx.
0.3 mg/L) in the diabetic SCID mice before the islet cell sheets were
transplanted (Fig. 3A). In the liver surface group, the serum insulin
level was signiﬁcantly increased to a level similar to that of the
normal SCID mice (1.19 ± 0.11 mg/L) after transplantation. The
serum insulin concentrations at days 14 and 28were 1.37 ± 0.43 mg/
L and 1.57 ± 0.23 mg/L, respectively. The subcutaneous space group
did not show a change in the serum insulin concentration
compared to the pre-transplant level. The insulin levels remained
consistently low for at least 28 days after transplantation.
Likewise, the levels of rat C-peptide in the subcutaneous space
group at days 14 and 28 were signiﬁcantly lower than those of the
liver surface group, although a slight increase of the rat c-peptide
level was observed (especially at day 14). These results clearly
suggested that the transplantation of islet cell sheets onto the liver
surface is more effective than that in the subcutaneous space, in
terms of insulin secretion and the subsequent achievement of
normoglycemia.
3.3. Functional assessment of transplanted islet cell sheets
To assess the glucose response ability of the transplanted islet
cell sheets in the diabetic mice, we performed an intraperitoneal
glucose tolerance test (IPGTT) at day 28 (Fig. 4). In the subcutaneous
space group, the blood glucose level consistently remained high
(>400 mg/dL) after glucose administration, as was the case for the
nontransplanted diabetic mice. In the liver surface group, the blood
glucose level reached themaximum (285.2 ± 38.2 mg/dL) at 30min
after glucose administration and then gradually decreased to the
normal levels within approx. 120 min. The glucose response curve
showed a pattern similar to that of the normal SCIDmice, indicating
that the transplanted islet cell sheets on the liver surface were
functional and capable of secreting an amount of insulin that was
sufﬁcient to achieve normoglycemia in response to glucose
administration.
3.4. Histological assessment of the transplanted islet cell sheets in
the liver
We performed a histological assessment on day 28 after
transplantation to investigate the graft survival and revasculari-
zation in the neo-islets created on the liver surface (Fig. 5),
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Fig. 2. Measurement of the blood glucose level and body weight of diabetic mice after islet cell sheet transplantation. (A, B) Fasting blood glucose levels (A) and body weights (B) in
diabetic SCID mice. Two islet cell sheets (total 1.6  106 cells) were transplanted onto the surface of the liver (circles: n ¼ 7) or into the subcutaneous space (triangles: n ¼ 7) of STZ-
induced diabetic SCID mice. The blood glucose level and body weight in the diabetic SCID mice without the transplantation of islet cell sheets was also monitored as a control
(squares: n ¼ 7). Data are mean ± SEM. *p < 0.05 vs. non-transplanted control.
Fig. 3. The serum concentrations of insulin and rat-speciﬁc C-peptide in diabetic mice after islet cell sheet transplantation. Islet cell sheets were transplanted onto the surface of the
liver or into the subcutaneous space of STZ-induced diabetic SCID mice. (A, B) The serum concentration of insulin (A) and rat-speciﬁc C-peptide (B) of diabetic SCID mice in the liver
surface (black bar: n ¼ 7) and subcutaneous (white bar: n ¼ 7) transplantation groups was measured by ELISA at 2 days prior to and 14 and 28 days after transplantation. The
concentrations of insulin and mouse-speciﬁc C-peptide in normal SCID mice (gray bar: n ¼ 7) were determined as a control. Data are mean ± SEM. *p < 0.05 vs. the subcutaneous
space group.
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improving graft survival and islet cell functions [28e30]. The
histological examination conﬁrmed that the transplanted islet cell
sheets were effectively engrafted between two liver lobes (Fig. 5A,
B), forming a neo-islet tissue with a thickness of 50e70 mm. In the
experimental procedure, the islet cell sheets transplanted on the
decapsulated surface of the left lateral lobe of the liver were
subsequently covered by the median lobe of liver at the time of
transplantation (Fig. 1), which prevented the adhesion of the islet
cell sheets to the parietal peritoneum. The decapsulation of the
liver promoted the engraftment of islet cell sheets to the liver
surface (data not shown).
In contrast to the native islet morphology, the engineered neo-
islet tissue between the liver lobes was horizontally long (Fig. 5A, B)
and consisted predominantly of insulin-positive b-cells (Fig. 5C).
Glucagon-positive a-cells were also present, but their number was
small and they were sparsely distributed in the neo-islet tissue.CD31-positive vascular networks containing blood cells were
formed in the neo-islet tissues at day 28 (Fig. 5B, D). b cell prolif-
eration and apoptosis were assessed by the double staining for
insulin/Ki67 and TUNEL staining, respectively. As a result,
0.95 ± 0.41% (n ¼ 5) and 0.06 ± 0.06% (n ¼ 5) of the insulinþ cells
were Ki-67- (Fig. 5E, F) and TUNEL-positive on day 28, respectively.
The ratios of Ki-67þ and TUNELþ cells were almost equal to those of
the b cells in normal pancreases [7,31]. These results, together with
the results on the levels of rat-speciﬁc C-peptide virtually un-
changed from day 14e28 (Fig. 3B), suggest the stable engraftment
of the transplanted islet cell sheets. Conversely, it was difﬁcult to
ﬁnd transplanted islet cells in the subcutaneous space group at day
28 (data not shown), suggesting that the grafts did not survive well
in the subcutaneous space. These results revealed that compared to
the subcutaneous space, a small mass of islet cells (total
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Fig. 4. IGTT results after islet cell sheet transplantation. Islet cell sheets were trans-
planted onto the surface of the liver or into the subcutaneous space of diabetic SCID
mice. Glucose was injected intraperitoneally into nontransplanted normal (squares:
n ¼ 7) and diabetic SCID mice (diamonds: n ¼ 7), transplanted diabetic SCID mice
(subcutaneous, triangles: n ¼ 7; liver surface, circles: n ¼ 7) on day 28. The blood
glucose level was monitored up to 120 min after glucose administration. Data are
mean ± SEM. *p < 0.05 vs. non-transplanted diabetic SCID mice.
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We reported an approach for creating neo-islet tissues in the
subcutaneous space of diabetic mice by transplanting islet cell
sheets prepared from dispersed islet cells [20]. However, a large
mass of islet cells (total 1.1  107 cells per mouse) was required to
achieve euglycemia in mice with STZ-induced diabetes. The most
likely reason for this insufﬁciency was that the transplanted cells
were neither viable nor functional because of the limited supply of
oxygen and nutrition caused by the lack of early neovascularization
[32]. In the present study, we selected the liver surface as a new site
for transplanting islet cell sheets for treating diabetic mice. Eugly-
cemia was successfully achieved with a lesser amount of islet cells
(total 1.6  106 cells per mouse) when the liver surface was used
compared to the transplantation into the subcutaneous space.
The immunohistochemical analysis showed that the vascular-
ized neo-islet tissues were formed on the liver surface, which may
have primarily contributed to the preservation of islet cell function
and viability. In marked contrast, viable islet cells could not be
found in the subcutaneous space group. In the subcutaneous space
transplantation, the inherent limitations including the lack of early
vascularization, induction of local inﬂammation, and mechanical
stress on the graft [33] potentially hampered the survival and
engraftment of the transplanted islet cell sheets prepared from
1.6  106 islet cells.
The intraportal transplantation of islets to the liver has been the
most prevalent, safe, and less-invasive procedure. Optimal sites for
islet transplantation have been explored to maximize the function
and survival of islet cells. In addition to the liver, researchers have
attempted to transplant islets to various sites including the
pancreas, kidney subcapsular space, subcutaneous space, spleen,
omental pouch, gastric submucosa, and peritoneal cavity [5,6,32]. A
reversal of hyperglycemia was achieved by using a smaller number
of islets when the liver, spleen, and kidney subcapsular space were
used, compared with other sites.
However, kidney and spleen as the transplantation sites do not
have substantial therapeutic advantages over the liver. First, the
kidney may not be metabolically suitable, because insulin secretedfrom the kidney does not reproduce its physiological behavior.
Moreover, the transplantation of islets under the kidney capsule is a
signiﬁcantly invasive operation. Splenic site remains at risk of
hemorrhage at the time of islet transplantation as well as the high
accessibility of lymphocytes to the graft. For these reasons, an
intrahepatic site has been considered to be particularly suitable for
islets transplantation. However, as mentioned above, multiple do-
nors are usually required to achieve insulin independence by the
intraportal transplantation procedure. Not only IBMIR, but also
graft hypoxia and the liver immune system are critical problems
[34]. In addition, the transplantable cell volume is limited in order
to avoid the acute portal thrombosis in the intraportal trans-
plantation protocol [35].
The liver surface is an attractive alternative site for islet trans-
plantation as it allows for the prevention of IBMIR by avoiding the
direct infusion of the blood ﬂow to the transplanted islets or islet
cells. The transplantation of islets or islet cells onto the liver surface
can potentially reduce the required mass of islet cells to reverse
hyperglycemia, but it has not been possible to stably immobilize
dispersed cells or cell aggregates onto the surface. Cell sheet
technology enables us to directly and stably transplant a cellular
construct to the surface of host tissues, with the help of the
extracellular matrix layer accumulated on the surface of the cell
sheets [11], which works as a natural glue.
Cell sheets composed of ﬁbroblasts, mesenchymal stem cells
(MSCs), and iPSC-derived hepatocytes have been transplanted to
the liver surface of mice [27,36,37]. The liver surface is advanta-
geous in terms of the high accessibility and the lesser invasiveness
with the use of a laparoscope. In addition, it would be possible to
remove the transplanted tissues on the liver surface by employing
radio-frequency, microwave, or laser ablation with a minimally
invasive procedure [38] when problems arise in the transplanted
cells. These are the primary reasons why we tested the liver surface
for islet cell sheet transplantation.
Islets are highly vascularized tissues in vivo, and the inner
vasculature is essential for effectively secreting insulin in
response to the blood glucose level [39]. Vascular connections
between the interior structure of islets and the surrounding tis-
sues are severed at the time of islet isolation by collagenase
treatment. Usually, revascularization for transplanted islets be-
gins several days after transplantation and is established within
10e14 days [40]. Nutrients and oxygen are supplied solely by
diffusion from the surrounding tissue to the transplanted islets
until the restoration of vascularization is completed. Limitations
of oxygen and nutrition supply cause the degradation of cell
functions and the poor survival of the transplanted islets. Small
islets, typically with sizes less than 100 mm, are therefore supe-
rior to larger islets, in both in vivo transplantation and in vitro
cultivation [24,41e43].
In our experiments, on the other hand, revascularization to the
transplanted islet cell sheets was signiﬁcantly promoted in the
liver surface group, forming densely vascularized neo-islet tissues.
This revascularization would have been accelerated by the geo-
metric characteristics of the thin cell sheets prepared using TRDs,
with the help of the effective interaction with the host liver sur-
face. Capillary networks formed in the islet cell sheets may also
have contributed to the enhancement of cell survival, function,
and engraftment.
We successfully transplanted islet cell sheets onto the liver
surface of diabetic mice with the combination of an efﬁcient re-
covery method by the in situ gelation of gelatin [27]. This in situ
gelation method improved the recovery efﬁciency of the islet cells
from TRDs compared to the conventional methods using the
membrane only [19,20]. However, a portion of the adhered islet
cells, at most ~20% of the cells, sometimes remained on and could
Fig. 5. Histological analysis of the islet cell sheets that were engrafted on the surface of the left lateral lobe of the liver and covered by the median lobe of the liver. (A, B) HE staining
of neo-islet tissues between liver lobes on day 28. Neo-islet tissue (black arrow heads) and vascular networks containing blood cells (white arrow heads) are shown. (C) Double
immunohistochemical staining for insulin (green) and glucagon (red) of neo-islet tissues in liver on day 28. (D) Double immunohistochemical staining for insulin (green) and CD31
(red) on day 28. (E, F) Double immunohistochemical staining for insulin (green) and Ki-67 (red) on day 28. Arrows denote Ki-67/insulin double positive b cells in the neo-islet tissue.
Bar: 50 mm.
I. Fujita et al. / Regenerative Therapy 8 (2018) 65e72 71not be recovered from the TRDs (data not shown) because of the
strong attachment of the islet cells to the TRDs, even though we
used TRDswith a higher amount of grafted temperature-responsive
polymer, poly(N-isopropylacrylamide). This suggested that an
improvement in the recovery and transfer methods of islet cell
sheets enables a further reduction of the required amount of islet
cells to reverse hyperglycemia in the present liver surface trans-
plantation procedure.
In a recent study, Hirabaru et al. created islet/MSC hybrid sheets
by seeding whole islets onto a conﬂuent layer of cells on MSCs [44].
Almost all of the cells were efﬁciently recovered from the TRDs,
because theMSCswere completely detachable from the TRDswhen
the culture temperature was decreased to 20 C. In addition, the
MSC sheets promoted angiogenesis by secreting hepatocyte growth
factor (HGF) and vascular endothelial growth factor (VEGF) at a
subcutaneous site. The use of such hybrid cell sheets composed of
dispersed islet cells and other types of cells may improve therecovery from TRDs and enhance the therapeutic efﬁcacy of islet
cell sheet transplantation.
5. Conclusions
Cell sheet technology enabled us to transplant islet cells to the
liver surface, which was demonstrated herein to be an efﬁcient and
favorable site for islet cells. The islet cell sheets, prepared from a
small number of dispersed islets (total 1.6  106 cells) and trans-
planted to the liver surface, normalized the blood glucose levels of
diabetic mice, whereas this did not occur in the case of the sub-
cutaneous space transplantation. Transplantation on the liver sur-
face led to improved engraftment, revascularization, and a long-
term survival of the islet cells, achieving euglycemia in STZ-
induced diabetic mice, even though we used a relatively small
mass of the islet cell sheets. The approach described herein may be
useful as a new method for the islet cell-based treatment of T1DM.
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